In January, ABC Affiliate KGO of San Francisco interviewed UCSF pediatric endocrinologist Stephen Rosenthal, MD concerning a study to help assess how a dietary supplement might prevent type 1 diabetes in high-risk infants.
Diabetes Center faculty member Mark Anderson, MD, PhD was one of only thirteen physicians awarded the Clinical Scientist Award in Translational Research this year by the Burroughs Wellcome Fund. This program supports established physician-scientists dedicated to translational “bench to bedside” research by providing grants of $750,000 over five years.
After being involved in diabetes and endocrine research at UCSF for nearly 40 years – a distinguished career that includes the breakthrough cloning of the growth hormone gene and first synthesis of growth hormone, the development of the UCSF Diabetes Center, the presidency of the Endocrine Society, and election to the prestigious National Academy of Sciences – you’d think John Baxter, MD would be ready to focus on his love of fishing. Instead of retirement, Dr.
Even the popular press is excited about recent developments involving anti-CD3, a potential type 1 therapy with strong ties to UCSF. In a recent issue of FORBES Magazine, senior editor Robert Langreth reveals the long history of anti-CD3 -- a monoclonal antibody that stops beta cell destruction.
Significant progress has been made in the past several years in improving the results of pancreatic islet transplantation for type 1 diabetics. Here at UCSF, we are very pleased with our success rate using a new enzyme that has helped to ensure islet viability through the transplant process.
Thanks to a generous gift made possible by a family whose lives have been impacted by type 1 diabetes, the Mary B. Olney MD / KAK Chair in Pediatric Diabetes and Clinical Research has been awarded to Steve Gitelman, MD, Director of the UCSF Pediatric Diabetes Program.
While leading the Department of Biochemistry and Biophysics and the Hormone Research Institute, William J. Rutter, PhD helped UCSF to make some of its most important contributions in biotechnology -- including the cloning of the genes for insulin and human growth hormone. It was these discoveries that spurred the creation of the world’s first biotech company, Genentech Inc., and Chiron Corp., the company Dr. Rutter co-founded.
To take a promising drug to market, it costs on average $500 million. Academic research institutions such as UCSF excel in conducting basic research and early stage human clinical trials, however, for cost reasons it is important that promising therapies are picked up by private industry.
Inflammation is a biological process driven by the immune system to help the body react to infection, irritation or other injury -- and help the body to repair itself. Researchers in the UCSF Helen Diller Family Comprehensive Cancer Center have learned that the mast cell, a cell of the immune system, plays an important role in inflammation.
Nearly two-thirds of US adults are overweight – fueling the twin epidemic of obesity and type 2 diabetes in this country. Allison Xu, an Assistant Professor who was trained at Stanford and joined the UCSF Diabetes Center in 2006, is focused on understanding how the central nervous system regulates body weight and glucose levels.
McGraw Hill has just published “Diabetes DeMystified: A Self-Teaching Guide”, written by our very own UCSF physician and clinical researcher, Umesh Masharani, M.D.
Have you or a loved one ever been frustrated by how your diabetes has been managed in a hospital setting? Thanks to a team of clinicians led by Robert Rushakoff, MD and Umesh Masharani, MD, UCSF has tackled this problem head on by putting in place new insulin management systems for patients with diabetes being treated in UCSF hospitals.
Feroz Papa, M.D., Ph.D. was awarded a prestigious New Innovator Award, one of only 29 investigators nationwide who received this award. The NIH created this new award to help stimulate highly innovative research and support promising new investigators.